ArticleOncology letters2017
MAPK/P53-mediated FASN expression in bone tumors.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Ufmylation-Deficient DDRGK1 Ameliorates Obesity by Inhibiting FASN-Mediated Adipocyte Lipogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence.Metabolites · 2023Review
- FASN Knockdown Inhibited Anoikis Resistance of Gastric Cancer Cells via P-ERK1/2/Bcl-xL Pathway.Gastroenterology research and practice · 2021Article
- Expression of miRNAs in plasma exosomes derived from patients with atrial fibrillation.Clinical cardiology · 2020Article
- Picropodophyllotoxin, an Epimer of Podophyllotoxin, Causes Apoptosis of Human Esophageal Squamous Cell Carcinoma Cells Through ROS-Mediated JNK/P38 MAPK Pathways.International journal of molecular sciences · 2020Article
- Association between different levels of lipid metabolism‑related enzymes and fatty acid synthase in Wilms' tumor.International journal of oncology · 2020Article
- Deregulation of Lipid Metabolism: The Critical Factors in Ovarian Cancer.Frontiers in oncology · 2020Review
- Article
- p53 and metabolism: from mechanism to therapeutics.Oncotarget · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The correlation between mitogen-activated protein kinase (MAPK)/P53 signaling-dependent fatty acid synthase (FASN) expression and bone tumors was examined in the present study. We established the SH081 bone tumor cell line, which was used to determine the expression of FASN and MAPK/P53 at the mRNA and protein levels in bone tumor cells and normal cells. Compared with the normal cells, the expression of MAPK/P53 and FASN mRNA was significantly elevated, whereas inhibition of MAPK/P53 decreased FASN expression. Similarly, the expression of FASN and MAPK/P53 proteins were significantly elevated in the bone tumor cells and treatment with the MAPK/P53 inhibitor decreased the expression of FASN. To determine the role of MAPK/P53 in cell proliferation, bone cancer cells were treated with MAPK/P53 inhibitor and the results showed a reduced proliferation rate. Thus, FASN promotes the development of bone tumors and MAPK/P53 signaling contributes to bone tumors by upregulating the expression of FASN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.